最高获近11亿美元里程碑付款，恒瑞医药再拿海外大单

Core Insights - Heng Rui Medicine has licensed its innovative drug SHR-A1811 to Glenmark Specialty for an upfront payment of $18 million, with potential milestone payments up to $1.093 billion [1] - The agreement grants Glenmark exclusive rights to develop and commercialize SHR-A1811 outside of 15 countries, including China, the US, Canada, Europe, and Japan [1] - The licensing deal is expected to enhance the global market reach of SHR-A1811 and improve Heng Rui's innovative brand and overseas performance [1] Product Development and Regulatory Status - SHR-A1811 has received orphan drug designation from the FDA for gastric cancer and gastroesophageal junction adenocarcinoma, and is set to be approved in China by May 2025 [1] - The drug has nine indications included in the breakthrough therapy list by the National Medical Products Administration, covering various cancers such as non-small cell lung cancer, breast cancer, and colorectal cancer [2] Company Performance and Recent Deals - Heng Rui Medicine has recently secured significant licensing agreements, including a $65 million upfront payment from BraveheartBio for another project, and a $500 million upfront payment from GSK for global rights to a different drug [2] - The company reported a revenue of 15.761 billion yuan for the first half of 2025, a year-on-year increase of 15.88%, and a net profit of 5.051 billion yuan, up 34.63% year-on-year [3]